精测电子公告，持股5%以上股东陈凯先生持有2252.98万股，占总股本8.05%；因自身资金需要，拟自 公告15个交易日后的3个月内（2026年3月6日至2026年6月5日）通过集中竞价或大宗交易减持不超500万 股，占1.79%，其中集中竞价减持不超1%，大宗交易减持不超2%。 ...

精测电子公告，持股5%以上股东陈凯先生持有2252.98万股，占总股本8.05%；因自身资金需要，拟自 公告15个交易日后的3个月内（2026年3月6日至2026年6月5日）通过集中竞价或大宗交易减持不超500万 股，占1.79%，其中集中竞价减持不超1%，大宗交易减持不超2%。 ...

大豪科技公告，截至公告日，董事股东吴海宏持股1.2亿股，占10.77%；谭庆9572.11万股，占8.57%； 股东孙雪理9572.11万股，占8.57%；赵玉岭8462.95万股，占7.58%。因个人资产配置，四股东拟于2026 年3月6日至2026年6月5日，通过集中竞价分别减持不超过1116.65万股，即各不超过1%。 ...

1.持有公司股份132,369,971股（占公司总股本1比例32.68%）的控股股东易瑞创投计划以集中竞价 或大宗交易方式减持其持有的公司股份合计不超过11,521,758股（占公司总股本比例2.84%）。 2.持有公司股份19,008,003股（占公司总股本比例4.69%）的股东易达瑞计划以集中竞价交易或大宗 交易的方式减持其持有的公司股份合计不超过288,500股（占公司总股本比例0.07%）。 中国经济网北京2月3日讯 易瑞生物(300942.SZ)昨晚披露关于控股股东及其一致行动人减持计划期 限届满暨减持结果的公告称，公司2025年10月13日披露了《关于控股股东及其一致行动人减持股份的预 披露公告》，控股股东易瑞（海南）创业投资有限公司（以下简称"易瑞创投"）及其一致行动人深圳易 达瑞管理咨询合伙企业（有限合伙）（以下简称"易达瑞"）和深圳易凯瑞管理咨询合伙企业（有限合 伙）（以下简称"易凯瑞"）计划于上述公告披露之日起15个交易日后的3个月内以集中竞价或大宗交易 方式减持公司股份，具体情况如下： | 股东 | 減持方式 | 减持期间 | 减持均价 | 减持股数 | 减持比例 | | --- | - ...

Core Viewpoint - Fulin Precision (300432) has been subjected to regulatory measures by the Sichuan Securities Regulatory Bureau due to various compliance violations, including governance, internal control, financial accounting, and information disclosure issues [1][2]. Group 1: Compliance Violations - The company governance issues include missing individual votes from board resolutions and lack of signatures from insiders on confidential information records [1]. - Internal control problems involve related party transactions where contracts were signed after the work commenced, and some revenue recognition documents were not retained [1]. - Financial accounting irregularities include misreported income from outsourced processing materials, premature revenue recognition for exports, and unaccounted inventory depreciation [1]. - Information disclosure failures consist of untimely and inaccurate disclosures regarding related party transactions and bad debt provisions [1]. Group 2: Regulatory Actions - The Sichuan Securities Regulatory Bureau has mandated corrective actions for Fulin Precision and issued warning letters to key executives, including the chairman and general manager [2]. - The company is required to rectify the identified compliance issues as part of the regulatory measures [2]. Group 3: Fundraising Activities - Fulin Precision announced a plan to raise approximately 3.18 billion yuan through a private placement, with proceeds allocated to various projects, including high-end lithium iron phosphate production and key components for electric vehicles [2][3]. - The placement involves a significant investment from CATL, which will acquire over 5% of Fulin Precision's shares, constituting a related party transaction [3]. Group 4: Shareholder Actions - The actual controller, An Zhifu, has completed a share reduction plan, selling a total of 17,097,476 shares at an average price of 15.48 yuan per share, amounting to approximately 265 million yuan [3]. - An Zhifu's total cash raised from share reductions in 2025 reached approximately 488 million yuan [5].

Core Viewpoint - The announcement details a share reduction plan by significant shareholders of Haishike Pharmaceutical Group Co., Ltd., indicating a total potential reduction of up to 10,000,000 shares, which is approximately 0.89% of the company's total share capital [2][3]. Group 1: Shareholder Information - Shareholder Hao Congmei holds 3,518,000 shares, representing 0.31% of the total share capital, while shareholder Yang Fei holds 42,442,286 shares, representing 3.79% of the total share capital [2]. - The reduction plan involves Hao Congmei planning to reduce up to 2,000,000 shares (0.18% of total share capital) and Yang Fei planning to reduce up to 8,000,000 shares (0.71% of total share capital) [3]. Group 2: Reduction Plan Details - The reduction will occur within three months following a 15 trading day period after the announcement, using block trades or centralized bidding [2][3]. - The reason for the reduction is stated as personal funding needs [3]. - The shares to be reduced were originally acquired through block trades in 2015 [3]. Group 3: Compliance and Commitments - The shareholders have committed to avoiding any competition with the company's main business and ensuring that any related transactions are conducted fairly and transparently [5]. - The shareholders confirm that there are no circumstances that would prevent them from reducing their shares as per the regulations [5].

Core Viewpoint - The company is undergoing restructuring due to significant financial losses and a court ruling accepting a reorganization application from a bank, indicating potential challenges ahead for its operations and stock performance [1] Financial Performance - In 2024, the company reported a revenue of 628 million, with a net loss of 714 million [1] - For the first three quarters of 2025, the company recorded zero revenue and a net loss of 977 million [1] Shareholder Actions - A major shareholder, Suzhou Qingsong, plans to reduce its holdings by up to 4 million shares, which represents 0.87% of the total share capital [1] Restructuring and Risks - The pre-restructuring work is currently in progress, with expectations of continued losses in 2025, which may lead to a risk warning for stock delisting [1] - The seamless clothing segment may also be adversely affected by the ongoing financial difficulties [1]

Core Viewpoint - The major shareholders of Yirui Biotechnology, including Yirui Venture Capital and its affiliates, have completed a share reduction, selling a total of 10.68 million shares, which represents 2.6366% of the total share capital [1] Share Reduction Details - Yirui Venture Capital reduced its holdings by 3.82 million shares through centralized bidding at an average price of 9.85 yuan per share and 6.23 million shares through block trading at an average price of 8.81 yuan per share [1] - Yidazhi reduced its holdings by 38,400 shares through centralized bidding at an average price of 9.85 yuan per share and 250,000 shares through block trading at an average price of 9.76 yuan per share [1] - Yikaire reduced its holdings by 91,800 shares through centralized bidding at an average price of 9.85 yuan per share and 25,000 shares through block trading at an average price of 9.76 yuan per share [1] Post-Reduction Shareholding Structure - After the reduction, Yirui Venture Capital holds 122 million shares, accounting for 30.1973% of the total shares [1] - Yidazhi holds 18.7196 million shares, accounting for 4.6213% of the total shares [1] - Yikaire holds 22.2354 million shares, accounting for 5.4893% of the total shares [1] - The combined holdings of the three parties amount to 223 million shares, representing 55.1625% of the total shares [1]

Core Viewpoint - Taxfriend Co., Ltd. (603171.SH) announced a share reduction plan by its controlling shareholder, Ningbo Sicheng Venture Capital Partnership, intending to sell up to 12,190,350 shares, representing a maximum of 3% of the company's total share capital, without changing the control of the company [1][2]. Group 1: Share Reduction Plan - Ningbo Sicheng plans to reduce its holdings from March 3, 2026, to June 2, 2026, through centralized bidding and block trading, with a total potential cash-out of approximately 892 million yuan based on the last closing price of 73.18 yuan per share [1]. - The total shares to be reduced include a maximum of 4,063,450 shares through centralized bidding (up to 1% of total shares) and 8,126,900 shares through block trading (up to 2% of total shares) [1]. Group 2: Current Shareholding Status - As of the announcement date, Ningbo Sicheng holds 209,914,539 shares, accounting for 51.66% of the total share capital, with these shares acquired before the IPO [1]. - Ningbo Sicheng and Zhang Zhengchao are acting in concert, with a combined holding of 302,214,539 shares, representing 74.37% of the total share capital [1]. Group 3: Previous Share Reductions - Since starting to reduce its holdings on March 14, 2025, Ningbo Sicheng has cumulatively reduced 13,181,200 shares, realizing approximately 623 million yuan [2]. - The previous reductions occurred at various average prices per share, with the highest average price being 52.73 yuan and the lowest at 43.14 yuan [3].

责任编辑：小浪快报 根据喜娜AI异动分析，博迁新材跌停原因可能如下，治理调整风险+股东减持+资产减值： 1、公司治理 结构调整带来不确定性：博迁新材取消监事会并大规模修订制度，虽程序合规且意在优化治理，但可能 削弱内部监督机制，部分股东对此存在顾虑。同时大规模制度变更需要较长适应和磨合期，这可能影响 公司短期运营效率。 2、大股东减持传递消极信号：新辉投资减持1%股份，套现1.22亿元，这种行为可 能向市场传递出股东对公司未来发展持谨慎态度的信号，引发投资者对公司前景的担忧，从而导致股价 下跌。 3、计提资产减值准备影响利润：2025年公司计提1327.36万元资产减值准备，这直接减少了当期 利润，对公司财务状况产生一定负面影响，进而影响投资者对公司的信心。从资金流向来看，大股东减 持可能引发资金流出，加上投资者信心受挫，资金流出进一步加剧，导致股价跌停。 声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整 ...